Papers/PMID:41087029
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.
Clinical and molecular hepatology2026The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
berberine — decreases alanine aminotransferase
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Findingreplicated ×1“However, oral administration of BBR not only reversed hepatocyte necrosis, but also decreased the elevated levels of TBA, ALP, TBIL, DBIL, ALT, and AST ( Supplementary Fig. 1A, 1B).”
Quoted verbatim from Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.. - Study
- animal · not in humans
- Duration
- 7 days
- Population
- C57BL/6J mice with bile duct ligation-induced cholestatic liver injury; serum ALT by automated biochemical analyser
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.2026PMID:41087029Permalink
berberine — decreases aspartate aminotransferase
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“However, oral administration of BBR not only reversed hepatocyte necrosis, but also decreased the elevated levels of TBA, ALP, TBIL, DBIL, ALT, and AST ( Supplementary Fig. 1A, 1B).”
Quoted verbatim from Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.. - Study
- animal · not in humans
- Duration
- 7 days
- Population
- C57BL/6J mice with bile duct ligation-induced cholestatic liver injury; serum AST by automated biochemical analyser
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.2026PMID:41087029Permalink